Genus plc GNS
LSE · United Kingdom · Process Industries
GBp 2,150.00+8.00 (+0.37%)
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · GBp · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Genus (LON:GNS) reported higher adjusted profit and cash generation for FY 2026, supported by growth in its porcine genetics business, efficiency gains in bovine genetics and contributions from joint ventures. The company also announced a £60 million share buyback and proposed a 10% increase in its
Genus has just seen its fair value estimate tweaked, with the price target adjusted from £31.63 to about £31.28 per share. This small move reflects a mix of optimism and caution in recent analyst commentary, where views on growth, execution risk, and required returns are being rebalanced. As you read on, you will see how these shifting assumptions shape the evolving Genus story and what to watch next in the narrative. Analyst Price Targets don't always capture the full story. Head over to our...
Genus has seen its modelled fair value move from £30.82 to £31.67, a small uplift that may still matter if you are tracking the shares closely. Analysts linking this £1.00 change to revised assumptions are effectively updating how they weigh Genus’ potential against execution risks, with bullish and cautious camps reading the same inputs in different ways. As you read on, you will see how these shifts fit into the broader analyst debate and what to watch as the narrative evolves. Analyst...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.